These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32755046)

  • 1. Effect of gender on transition of normo- to microalbuminuria under angiotensin receptor blocker therapy in diabetes.
    Scurt FG; Menne JJ; Korda A; Haller H; Chatzikyrkou C
    J Diabetes; 2020 Nov; 12(11):856-859. PubMed ID: 32755046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
    Arai K; Morikawa Y; Ubukata N; Sugimoto K
    Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Ritz E; Viberti GC; Ruilope LM; Rabelink AJ; Izzo JL; Katayama S; Ito S; Mimran A; Menne J; Rump LC; Januszewicz A; Haller H
    Diabetologia; 2010 Jan; 53(1):49-57. PubMed ID: 19876613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.
    Menne J; Ritz E; Ruilope LM; Chatzikyrkou C; Viberti G; Haller H
    J Am Heart Assoc; 2014; 3(2):e000810. PubMed ID: 24772521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
    Bilous R; Chaturvedi N; Sjølie AK; Fuller J; Klein R; Orchard T; Porta M; Parving HH
    Ann Intern Med; 2009 Jul; 151(1):11-20, W3-4. PubMed ID: 19451554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
    Ikeda H; Hamamoto Y; Honjo S; Nabe K; Wada Y; Koshiyama H
    Diabetes Res Clin Pract; 2009 Jan; 83(1):117-8. PubMed ID: 19062123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.
    Abe M; Oikawa O; Okada K; Soma M
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):159-64. PubMed ID: 25287898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
    Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
    J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
    Haller H; Ito S; Izzo JL; Januszewicz A; Katayama S; Menne J; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G;
    N Engl J Med; 2011 Mar; 364(10):907-17. PubMed ID: 21388309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
    Consuegra-Sánchez L; Sanchis J; Núñez J; Cascón JD; Villegas M; Picó F
    Rev Esp Cardiol (Engl Ed); 2012 Apr; 65(4):378-80. PubMed ID: 21840109
    [No Abstract]   [Full Text] [Related]  

  • 13. Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.
    Morikawa A; Ishizeki K; Iwashima Y; Yokoyama H; Muto E; Oshima E; Sekiguchi M; Miura T; Itoh H; Haneda M
    Clin Exp Nephrol; 2011 Dec; 15(6):848-53. PubMed ID: 21823043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of microalbuminuria in type 2 diabetes: lessons learned from the ROADMAP study.
    Ritz E; Menne J; Haller H
    Nephrol Dial Transplant; 2012 Dec; 27 Suppl 4():iv28-30. PubMed ID: 23258807
    [No Abstract]   [Full Text] [Related]  

  • 15. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.
    Lindhardt M; Persson F; Zürbig P; Stalmach A; Mischak H; de Zeeuw D; Lambers Heerspink H; Klein R; Orchard T; Porta M; Fuller J; Bilous R; Chaturvedi N; Parving HH; Rossing P
    Nephrol Dial Transplant; 2017 Nov; 32(11):1866-1873. PubMed ID: 27507891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
    Elajami TK; Alfaddagh A; Lakshminarayan D; Soliman M; Chandnani M; Welty FK
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28710178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
    Chatzikyrkou C; Menne J
    Expert Rev Cardiovasc Ther; 2012 Sep; 10(9):1087-92. PubMed ID: 23098143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.
    Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S;
    Hypertens Res; 2008 Apr; 31(4):657-64. PubMed ID: 18633177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
    Ohtomo S; Ito M; Izuhara Y; Van Ypersele De Strihou C; Miyata T
    Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M; Okubo S; Mizubayashi R; Isaka N; Machida H; Okamoto S; Hirota H; Takeuchi M; Kato T; Nakatani K; Mizuno O; Miyagawa K; Makino K; Okura T; Dohi Y; Ito M; Kimura G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.